^
BIOMARKER:

Inflammatory gene signature

Inflammatory gene signature
NSCLC
pembrolizumab
Sensitive: C3 – Early Trials
Inflammatory gene signature
NSCLC
nivolumab
Sensitive: C3 – Early Trials